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Original Study

Clinical and Disease Characteristics From
REVEAL at Time of Enrollment (Baseline):
Prospective Observational Study of Patients With
Polycythemia Vera in the United States
Michael R. Grunwald,1 Brady L. Stein,2 Ralph V. Boccia,3 Stephen T. Oh,4
Dilan Paranagama,5 Shreekant Parasuraman,5 Philomena Colucci,5 Ruben Mesa6
Abstract
REVEAL is the ﬁrst large, prospective observational study aimed at examining the contemporary
demographics, burden of disease, clinical management, patient-reported outcomes, and health care resource
utilization in patients with polycythemia vera in the United States.
Background: Polycythemia vera (PV) has a prevalence of 44 to 57 per 100,000 people in the United States.
Prospective data concerning the demographics, clinical characteristics, and treatment patterns of patients with PV in
the United States are lacking. Patients and Methods: The ongoing, prospective, observational REVEAL study
evaluates demographics, disease burden, clinical management, patient-reported outcomes, and health care resource
utilization of adult patients with PV in the United States. This report summarizes the demographics and clinical
characteristics of patients at enrollment (baseline). Results: Patients (n ¼ 2510) were a median age of 67.0 years,
54.2% were male, and 89.1% were white. The median time from PV diagnosis to study enrollment was 4.0 (range,
0-56.3) years. Most patients (89.7%) were diagnosed after an abnormal blood test. Less than half (49.2%) underwent
JAK2 mutation analysis, of whom 95.8% were JAK2 V617F mutation positive; < 1% were positive for JAK2 exon 12
mutations. At enrollment, 47.7% of patients had elevated hematocrit (> 45%), 35.8% had elevated platelets (> 400 
109/L), and 37.0% had elevated leukocytes (> 10  109/L). Most patients (94.5%) were receiving active PV treatment,
predominantly therapeutic phlebotomy alone (33.6%), hydroxyurea monotherapy (29.0%), or hydroxyurea plus
phlebotomy (23.7%). Thrombotic events occurred in 11.9% of patients before PV diagnosis (venous, 6.7%; arterial,
5.7%), and 8.3% between diagnosis and enrollment. Hypertension (70.6%) was the most common previous medical
condition. Conclusion: REVEAL enrollment data inform our understanding of the baseline demographics, diagnostic
approach, disease characteristics, and treatment patterns of patients with PV in the United States. Longitudinal realworld data collected in this study will complement information collected during randomized controlled clinical trials.
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18, No. 12, 788-95 ª 2018 The Authors. Published by Elsevier Inc. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Blood tests, Demographics, JAK2 V617F mutation, Myeloproliferative neoplasm, Population characteristics

Introduction
Polycythemia vera (PV) is a myeloproliferative neoplasm in
which clonal proliferation of a hematopoietic progenitor cell results
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in erythrocytosis, leukocytosis, and thrombocytosis.1 With respect
to the epidemiology of PV in the United States, analyses of
administrative claims from 2008 to 2010 reported a prevalence of
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approximately 44 to 57 per 100,000 people.2 Most patients with
PV have a Janus kinase 2 (JAK2) mutation that results in constitutive activation of hematopoietic signal transduction, thus
explaining the exaggerated hematopoiesis. More than 95% of patients with PV carry the JAK2 V617F mutation; w4% have mutations in JAK2 exon 12.3-7
Patients with PV have an increased mortality risk relative to the
general population, primarily due to thrombotic events, transformation to leukemia or myeloﬁbrosis, and solid tumors.8-12 Patients also experience a broad range of symptoms that may lead to
decreased quality of life and productivity.13-16
Large multicenter observational studies of PV have focused
primarily on European patients,13,14,16-21 whereas US studies have
been limited to single-center settings.22,23 Patterns of care can be
characterized with administrative claims databases and electronic
medical record audits. However, these data sources frequently lack
important clinical information and do not capture patient-reported
outcomes (PROs).
The Prospective Observational Study of Patients With Polycythemia
Vera in US Clinical Practices (REVEAL; ClinicalTrials.gov,
NCT02252159) was designed to collect contemporary demographics
and data on the burden of disease, clinical management, PROs, and
health care resource utilization of US patients with PV being seen at
community and academic medical centers. This report describes the
demographics as well as the clinical and disease characteristics of patients in the REVEAL study at the time of study enrollment.

This analysis describes patient demographics as well as clinical
and disease characteristics at time of diagnosis and around the time
of enrollment. Historic data pertaining to the evaluations and disease characteristics at time of diagnosis and physician-reported data
from usual care visits, including information from the 6 months
before enrollment, were collected and abstracted from electronic
medical records into an electronic data capture system. For the
purpose of this analysis, physician-reported data in the following
categories were examined: demographics and PV disease characteristics; education, employment, insurance, and residency characteristics; laboratory tests and procedures used to determine a diagnosis
of PV; signs and symptoms at time of PV diagnosis; laboratory
values at time of enrollment; PV-directed therapy; comorbid conditions; thrombotic event history; concomitant medications; and
health care resource utilization.
The Charlson Comorbidity Index (CCI) was used to assess
morbidity.25 The CCI uses a 6-point scale to rate diagnosis codes
from the International Classiﬁcation of Diseases for each comorbid condition, which are summed to generate a total index score
for each patient; higher scores correspond with more severe
morbidity.

Patients and Methods

Statistical Analysis

Study Design

Descriptive statistics were used. Missing data were not imputed;
however, missing dates for temporal end points were imputed when
applicable. If the entire date (ie, day, month, and year) was missing,
all corresponding data were excluded from analyses involving dates.
If the day was missing but the month and year were available, the
date was imputed as the ﬁrst day of the month. If the day and
month were missing but the year was available, the date was
imputed as January 1.

REVEAL is a multicenter, noninterventional, prospective observational study of patients with PV conducted in accordance with the
Declaration of Helsinki. Approval of all study materials by central
(Sterling IRB; Atlanta, GA) and local institutional review boards
and provision of informed consent by all patients was required,
including a separate informed consent form documenting willingness to participate in an optional biological substudy to examine the
molecular features of PV. Patients with a clinical diagnosis of PV
were enrolled from community practices and academic centers in
the United States over a 24-month enrollment period. Physician
assessments and PRO outcomes (previously published24) were
recorded during routine care visits (approximately every 6 months).
Blood samples were collected at enrollment and annually for patients agreeing to participate in an optional molecular substudy. All
treatment decisions during the study were made by patients’ treating
physicians.

Eligibility Requirements
At enrollment, patients were  18 years old; had a clinical
diagnosis of PV per physician judgment; were willing and able to
provide informed consent and complete patient assessments and
questionnaires, either alone or with minimal assistance from a
caregiver or trained site personnel; and were currently under
physician supervision for management of PV. Patients were
excluded if they were participating in an active, blinded clinical trial;
had a life expectancy < 6 months; had a diagnosis of myeloﬁbrosis,
acute myeloid leukemia, or myelodysplastic syndrome; had a history

of or active plan (within 3 months of enrollment) to proceed to
allogeneic hematopoietic stem-cell transplantation; or had undergone splenectomy.

Assessments

Results
Patient Demographics and PV Disease Characteristics
In this ongoing study, 2510 patients were enrolled from July 22,
2014, to August 3, 2016, from 227 US sites (39 academic and
188 community [self-identiﬁed]; Figure 1). Patients had a mean
(SD) age of 66.3 (12.3) years (Table 1), and 2.9% were young
(aged < 40 years). Most patients were male (54.2%) and white
(89.1%), and 48.1% had a history of smoking; 11.1% were active
smokers at time of enrollment. Family history of PV was documented in 132 patients (5.3%).
Median (range) disease duration was 4.0 (0-56.3) years
(Figure 2), 77.3% of patients were classiﬁed as having high-risk
disease (aged  60 years and/or history of thrombotic events),
and 72.6% were obese or overweight. Spleen assessment by physical
examination was performed in 1601 patients (63.8%) at time of
enrollment. Of these patients, 282 (17.6%) had palpable splenomegaly. Spleen length measurements were available for 122 patients,
51.6% of whom had spleen length  5 cm from the left costal
margin to the point of greatest splenic extension.
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REVEAL Preliminary Report
Figure 1 IRB-Approved Study Sites Participating in REVEAL. A Total of 2510 Patients Were Enrolled From 227 Sites Across the United
States (39 Academic and 188 Community [Self-identiﬁed])

Abbreviations: IRB ¼ institutional review board; REVEAL ¼ Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices.

Patient Education, Employment, Insurance, and
Residency Characteristics
Most patients (62.7%) had at least some college education,
33.5% were employed full time or part time, 51.1% were retired,
and 4.4% were disabled or unable to work (Supplemental Table 1).
The vast majority of patients (99.1%) had health insurance (public
only, 47.8%; private only, 40.4%; both public and private, 10.9%).
Most patients (94.9%) were living independently at home, 3.7%
were living as a dependent at home, and 0.8% were living in assisted
housing; 0.1% and 0.4% were living in long-term care facilities or
other residency settings, respectively.

PV Diagnosis

790

-

The majority of patients were reported to have abnormal hemoglobin (59.0%) or hematocrit (57.5%) results at time of diagnosis (Table 2). An abnormal platelet count or erythropoietin level
was reported in only 28.7% and 20.1% of patients at time of
diagnosis, respectively. In almost half (49.2%) of patients, JAK2
mutational testing results were reported; most of these patients were
positive for JAK2 V617F (95.8%), with only 0.8% positive for
JAK2 exon 12 mutations. A JAK2 test was reported for 19.9% of
patients diagnosed before January 1, 2006, compared to 54.3% of
patients diagnosed after January 1, 2006. Bone marrow biopsy/
aspiration results were reported in 24.4% of patients. Palpable
splenomegaly was reported as a factor in the diagnosis of 7.0% of
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patients. With respect to PV-speciﬁc symptoms, the most
commonly reported symptoms noted at diagnosis were tiredness
(22.0%), itching (13.9%), muscle aches and/or bone pain (8.8%),
and difﬁculty sleeping (7.8%; Table 2).

Laboratory Values
At time of enrollment, 5.3% of patients had an elevated hemoglobin level (> 18.5 g/dL in men or > 16.5 g/dL in women),
47.7% had elevated hematocrit (> 45%), 35.8% had elevated
platelets (> 400  109/L), and 37.0% had elevated leukocytes
(> 10  109/L). Mean hemoglobin, hematocrit, platelet, and
leukocyte values at enrollment were 14.5 g/dL, 45%, 367.5 
109/L, and 10.4  109/L, respectively (Table 3).

PV-Directed Therapy at Time of Enrollment
At time of enrollment, the majority (54.6%) of patients with lowrisk disease were being managed with therapeutic phlebotomy.
However, 18.1% and 15.8% of low-risk patients were being
managed with hydroxyurea alone and phlebotomy plus hydroxyurea, respectively. Only 4.9% of patients with low-risk PV were
managed with watchful waiting. In contrast, hydroxyurea alone
(32.2%) and phlebotomy alone (27.4%) were the most commonly
reported PV-directed therapies in patients with high-risk PV.
Management with watchful waiting was reported for 5.7% of patients with high-risk disease (Figure 3). The most common

Michael R. Grunwald et al
Table 1 Demographics and PV Disease Characteristics at
Enrollment for 2510 Patients
Characteristic

Figure 2 Duration of Disease at Enrollment. *Excluding 25
Patients With Missing Diagnosis Date

Value

Age (y)

<1 y

Mean (SD)

66.3 (12.3)

Median (range)

67.0 (22.0-95.0)

Male sex

1360 (54.2)

Missing
1.0%

21.7%

≥15 y
7.5%

BMI (kg/m2) (n [ 2502)
Mean (SD)

28.7 (5.8)

Median (range)

28.0 (13.7-56.6)

10–<15 y

11.0%

35.4%
1–<5 y

Smoking
Ever smoked
Smoking at baseline

1208 (48.1)
23.4%

279 (11.1)

Race
White
Black or African American

2237 (89.1)

5–<10 y

143 (5.7)

Asian

37 (1.5)

Other

19 (0.8)

No information/missing

74 (2.9)

Evaluated,* n
Median (range), y

2485
4.0 (0–56.3)

Ethnicity
Non-Hispanic/Latino
Hispanic/Latino
No information/missing
Time from PV diagnosis to enrollment (y)
(n ¼ 2485), median (range)

2293 (91.4)
98 (3.9)
119 (4.7)
4.0 (0-56.3)

History of Thrombosis

Spleen Palpation
Spleen palpation performed
Patients with palpable spleen

malignancies included prostate (2.9%), breast (1.9%), and colon
(1.0%) cancers (Supplemental Table 2).

1601 (63.8)
282 (11.2)

PV Risk
Low

570 (22.7)

Higha

1940 (77.3)

History of thrombosis (venous or arterial)

500 (19.9)

Positive family history of PV

132 (5.3)

Data are presented as n (%) unless otherwise indicated. Sample size is 2510 unless otherwise
indicated.
Abbreviations: BMI ¼ body mass index; PV ¼ polycythemia vera.
a
Aged  60 years and/or history of thrombotic events.

hydroxyurea daily doses were 500 mg (35.4%) and 1000 mg
(30.2%). The mean hydroxyurea daily doses were 769.5 and 834.9
mg for patients undergoing and not undergoing phlebotomy,
respectively. Among patients who were treated with therapeutic
phlebotomy, mean number of phlebotomies was 2.5 (median, 2)
during the 6 months before enrollment. A small proportion of
patients were treated with other agents (8.2%), including ruxolitinib
(3.8%), anagrelide (2.0%), and interferon (1.4%).

Comorbid Conditions
The most common comorbid conditions were hypertension
(70.6%), hyperlipidemia (30.4%), obesity (17.5%), and diabetes
mellitus (15.7%). Mean (SD) CCI was 3.4 (0.83). A history of skin
cancer (not otherwise speciﬁed) and nonmelanoma skin cancer was
documented in 3.5% and 3.3% of patients, respectively. Malignant
melanoma was noted in 1.1% of patients. A history of other

At time of study enrollment, for patients with a known PV
diagnosis date (n ¼ 2485), 468 patients (18.8%) had a documented
thrombotic event (Table 4), and 4.6% had at least 2 thrombotic
events. Venous thrombotic events had occurred in 279 patients
(11.2%); the most common were deep vein thrombosis (6.1%) and
pulmonary embolism (2.6%). Arterial thrombotic events had
occurred in 218 patients (8.8%); the most common were cerebrovascular arterial thrombosis (5.1%) and acute myocardial infarction
(1.8%). A total of 29 patients (1.2%) experienced both a venous
and arterial thrombotic event. Before PV diagnosis, 296 patients
(11.9%) experienced thrombotic events (venous, 6.7%; arterial,
5.7%). Between diagnosis and enrollment, 207 patients (8.3%)
experienced a thrombotic event (venous, 5.2%; arterial, 3.5%). Of
the patients who experienced thrombotic events before PV diagnosis, 35 (11.8%) had a subsequent thrombotic event after PV
diagnosis. The exposure-adjusted thrombotic event rate between
diagnosis and enrollment was 1.55 per 100 patient-years. Among
patients who did not have a history of thrombotic events at time of
diagnosis, 7.0% had a thrombotic event after diagnosis.

Concomitant Medications
The 3 most common categories of concomitant medications were
statins (26.3%), selective b-blocking agents (18.9%), and
angiotensin-converting enzyme inhibitors (16.6%). Aspirin use was
reported in 62.9% of patients.

Health Care Resource Utilization
There were 667 patients (26.6%) who reported at least one
hospital, urgent care, emergency room, or outpatient visit within the
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Table 2 Abnormal Laboratory Tests and Polycythemia Verae
Related Signs and Symptoms at Time of Diagnosis in
2510 Patients

Table 3 Polycythemia VeraeRelated Laboratory Values at
Enrollment in 2510 Patients
Characteristic

Characteristic

Value

Abnormal Laboratory Testa

No. evaluated

Hemoglobin

1482 (59.0)

Mean (SD; range) (g/dL)

Hematocrit

1443 (57.5)

Elevateda

Platelet count

720 (28.7)

Hematocrit

White blood cell count

499 (19.9)

No. evaluated

Erythropoietin level

505 (20.1)

Mean (SD; range) (%)

Red blood cell count

454 (18.1)

Red cell mass

105 (4.2)

Platelet Count

Serum LDH

88 (3.5)

No. evaluated

EEC growth

8 (0.3)

Palpable splenomegaly
Mutational Test

> 45%

Mean (SD; range) (109/L)

175 (7.0)

> 400  109/L

1236 (49.2)

Leukocyte Count

JAK2 V617F, n/N (%)b

1184/1236 (95.8)

No. evaluated

JAK2 other, n/N (%)b

10/1236 (0.8)

Mean (SD; range) (109/L)

Missing, n/N (%)b

42/1236 (3.4)

> 10  109/L

Bone marrow test

Value

Hemoglobin

612 (24.4)

2241
14.5 (1.9; 8.2-22.1)
118 (5.3%)
2242
45 (5.7; 25-70)
1070 (47.7%)
2212
367.5 (186.4; 15.0-1542.0)
792 (35.8%)
2219
10.4 (7.2; 0.70-151.3)
821 (37.0%)

Deﬁned as > 18.5 g/dL for men and > 16.5 g/dL for women.

a

Symptoms (Documented by
Physician)
Tiredness

552 (22.0)

Itching

349 (13.9)

Muscle aches and/or bone pain

220 (8.8)

Difﬁculty sleeping

195 (7.8)

Data are presented as n (%) unless otherwise indicated.
Abbreviations: EEC ¼ endogenous erythroid colony; JAK2 ¼ Janus kinase 2; LDH ¼ lactate
dehydrogenase.
a
As reported by survey respondents; deﬁnitions of “abnormal” were not available. A patient
could be counted in > 1 category.
b
Denominator of 1236 is number of patients who had mutational analysis data from peripheral
blood test or other test.

6 months before enrollment. Most of these patients (82.6%) reported having outpatient medical care visits. PV was a causal factor
for 39.9% of all hospital, urgent care, emergency room, and
outpatient visits.

Discussion

792
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The REVEAL study is the ﬁrst large, prospective observational
study to examine the contemporary demographics, burden of disease, clinical management, PROs, and health care resource utilization among US patients with PV. Enrolled patients represent a
broad, real-world segment of the PV population who are actively
being managed at community or academic centers. In this analysis
of clinical and disease characteristics at time of enrollment to
REVEAL, patients were mostly male (54.2%) and had a mean (SD)
age of 66.3 (12.3) years, with a median (range) PV disease duration
of 4.0 (0-56.3) years. In the Cytoreductive Therapy in Polycythemia Vera (CYTO-PV) study, which had similar eligibility
criteria, 62.2% were male, mean (SD) age at recruitment/enrollment was 65 (12) years, and mean (SD) time from diagnosis to
enrollment was 4.3 (5.4) years.26 Baseline data reported from the
1638 patients included in the database collected during the observational study of the European Collaboration on Low-Dose Aspirin
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in Polycythemia Vera (ECLAP) project revealed that 57.5% were
male, mean (SD) age at recruitment/enrollment was 60 (13) years,
and mean (SD) time from diagnosis to enrollment was 5.0 (5.0)
years.27 Demographic statistics from REVEAL are similar to those
reported by other highly regarded studies.
Bone marrow biopsy and JAK2 mutation testing are important to
differentiate between a PV diagnosis and myeloﬁbrosis or essential
thrombocythemia; conﬁrmation of diagnosis by bone marrow biopsy may affect treatment selection and potentially outcomes. At
the time of diagnosis, it was reported that < 25% of patients underwent bone marrow biopsy/aspiration, and < 50% underwent
JAK2 mutation testing. Of the patients who did undergo JAK2
mutation testing, approximately 96% had a JAK2 V617F mutation,
and approximately 1% had other JAK2 mutations (eg, exon 12).
Because the majority of patients did not have JAK2 mutation testing
to verify diagnosis, it is possible that some do not truly have PV.
Importantly, JAK2 mutation testing is increasing over time. According to data reported in this study, of the patients diagnosed in
the 3-year intervals of 2005-2007, 2008-2010, 2011-2013, and
2014-2016, 38%, 57%, 57%, and 61% underwent JAK2 mutation
testing, respectively. However, even when taking into consideration
that the JAK2 mutation was discovered in 2005 and the time
needed for this mutation testing to become widely available to all
practice settings, the rates of JAK2 mutation testing reported in this
study seem low. Similarly, the percentage of patients who reportedly
underwent bone marrow biopsy and/or erythropoietin testing seems
low. These low rates may be related to the various ways in which
these data are acquired, recorded, and abstracted from electronic
medical records.28
Regarding the management of patients with low-risk disease, in
line with National Comprehensive Cancer Network clinical practice
guidelines,29 the majority (54.6%) of patients were managed with
phlebotomy with or without aspirin. However, > 40% of low-risk

Michael R. Grunwald et al
Figure 3 PV-Related Treatment at Enrollment. For “Other Agents,” Patients Could Be Counted in More Than One Category; Treatment
Included Ruxolitinib (3.8%), Anagrelide (2.0%), Interferons (1.4%), and Other (1.2%). Treatment Was Unknown for 2 Patients

Missing
0.1%

Watchful waiting ± aspirin
Other agents
8.2%

Phlebotomy +
hydroxyurea

Phlebotomy ±
33.6% aspirin

23.7%

29.0%
Hydroxyurea ± aspirin

PV-Related Treatment at Enrollment in Low- and High-Risk Patients
High-risk patients
Age
TE
Age ≥60 y +
Low risk
≥60 y
History
TE history
Treatment, n (%)
(n=570)
(n=1440)
(n=125)
(n=375)
Phlebotomy ±
311 (54.6) 402 (27.9)
48 (38.4)
82 (21.9)
aspirin
Hydroxyurea ±
103 (18.1) 464 (32.2)
35 (28.0)
125 (33.3)
aspirin
Phlebotomy +
90 (15.8)
388 (26.9)
20 (16.0)
96 (25.6)
hydroxyurea
Other agents
38 (6.7)
106 (7.4)
16 (12.8)
46 (12.3)
Watchful waiting ±
28 (4.9)
78 (5.4)
6 (4.8)
26 (6.9)
aspirin
Missing
0
2 (0.1)
0
0

All
patients
(N=1940)
532 (27.4)
624 (32.2)
504 (26.0)
168 (8.7)
110 (5.7)
0

PV, polycythemia vera; TE, thrombotic event.

patients received hydroxyurea or some other cytoreductive therapy
with or without aspirin. Conversely, approximately one third of
high-risk patients were managed without cytoreductive medications
with or without aspirin. These data suggest variance from guidelinedeﬁned risk-adapted treatment of PV, which was published after
many of these patients were diagnosed and enrolled.30 It is
important to note that treatment with aspirin was reported in
62.9% of patients, but it is likely that, in some patients, over-thecounter use of aspirin was not reported or recorded.
With respect to thrombotic events, 11.9% of patients in
REVEAL experienced thrombotic events before PV diagnosis
(venous, 6.7%; arterial, 5.7%), and 8.3% experienced a thrombotic
event between diagnosis and enrollment. In comparison, 14% of
patients with PV had thrombotic events before diagnosis, and 19%
had a thrombotic event during a 20-year follow-up in a retrospective
study of 1213 patients in Italian hematology institutions conducted
in 1995.18

Conclusion
As the ﬁrst prospective observational study of its size to assess US
patients with PV, REVEAL is expected to provide information that
will improve our understanding of the demographics, diagnosis,
management, and outcomes of these patients. This analysis describes patient demographics as well as clinical and disease characteristics at the time of diagnosis and around the time of enrollment.
REVEAL baseline data indicated that the JAK2 V617F mutation
rate among patients who underwent molecular testing was consistent with previous reports.4,31 However, the reported percentage of
patients who underwent testing was much lower than expected,
which could be related to the challenges of capturing retrospective
data from medical records. Many patients had poorly controlled
hematocrit, platelet, and leukocyte counts at enrollment, with
elevated hematocrit values observed in nearly half of all evaluated
patients. Additional prospective data from REVEAL (eg, treatment
patterns, PROs, and cardiovascular risk assessments) will be
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Table 4 History of Thrombotic Events in 2485 Patients With
Evaluable Data
Thrombotic Event
Any Events Before Enrollmenta
Before diagnosisb

N (%)
468 (18.8)
296 (11.9)

Venous

166 (6.7)

Arterial

142 (5.7)

Between diagnosis and enrollmentb
Venous
Arterial
More than one thrombotic event
Venous Events Before Enrollment
Deep-vein thrombosis

207 (8.3)
130 (5.2)
87 (3.5)
115 (4.6)
279 (11.2)
151 (6.1)

Pulmonary embolism

64 (2.6)

Superﬁcial venous thrombosis

30 (1.2)

Portal vein thrombosis

20 (0.8)

Cerebral vein/sinus thrombosis

17 (0.7)

Splenic vein thrombosis

9 (0.4)

Retinal vein thrombosis

7 (0.3)

Visceral/splanchnic vein thrombosis
Other
Arterial Events Before Enrollment
Cerebrovascular arterial thrombosis

1 (<0.1)
42 (1.7)
218 (8.8)
126 (5.1)

Acute myocardial infarction

44 (1.8)

Peripheral arterial thrombosis

14 (0.6)

Splenic infarction

6 (0.2)

Retinal artery thrombosis

4 (0.2)

Visceral arterial thrombosis
Other

1 (<0.1)
38 (1.5)

Patients without known PV diagnosis date were excluded from evaluable patient population.
a
Thrombotic events without event dates were excluded.
b
Patient groups reporting events “before diagnosis” and “between diagnosis and enrollment”
are not mutually exclusive.

important for understanding how the disease progresses and how
management changes with time.

history of thrombosis). In high-risk patients ( 60 years and/or
with a history of thrombosis), cytoreductive therapy is usually
added to phlebotomy and aspirin. Data collected from REVEAL
suggest variance from guideline-deﬁned risk-adapted treatment
of PV.
 During treatment, patients with PV should be monitored every 3
to 6 months for new thrombohemorrhagic events, increased
need/intolerance of phlebotomy, progressive/symptomatic
splenomegaly, symptomatic thrombocytosis, progressive leukocytosis, and progressive disease-related symptoms. This close
clinical surveillance is necessary to determine whether a cytoreductive therapy is indicated for low-risk patients or whether a
different medication should be selected for high-risk patients.
 Baseline characteristics of patients with PV enrolled in
REVEAL are similar to those reported by other highly regarded
studies.
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neoplasm that can be diagnosed on the basis of absolute erythrocytosis (hemoglobin > 16.5 g/dL in men, hemoglobin
> 16 g/dL in women), bone marrow biopsy, and the presence of
JAK2 V617F or JAK2 exon 12 mutation. According to World
Health Organization PV diagnostic criteria, bone marrow biopsy
may not be required in cases of sustained absolute erythrocytosis
(hemoglobin > 18.5 g/dL in men or > 16.5 g/dL in women) in
the presence of one of the JAK2 mutations and a subnormal
serum erythropoietin level.
 In this observational study, the retrospective review and
abstraction of data from electronic medical records limits
deﬁnitive conclusions regarding diagnostic approach.
 The primary goal of treatment is prevention of arterial and venous
thrombotic events. In general, risk-adapted treatment consists of
phlebotomy and aspirin in low-risk patients (< 60 years and no
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Supplemental tables accompanying this article can be found in
the online version https://doi.org/10.1016/j.clml.2018.08.009.
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REVEAL Preliminary Report
Supplemental Table 1 Education, Employment, Insurance,
and Residency Characteristics at
Enrollment for 2510 Patients
Characteristic

N (%)

Highest Level of Education
Less than high school

114 (4.5)

High school graduate/equivalent

805 (32.1)

Some college

556 (22.2)

College degree

686 (27.3)

Graduate degree

332 (13.2)

Missing

17 (0.7)

Current Employment Statusa
Full-time employee

721 (28.7)

Part-time employee

119 (4.7)

Homemaker
Student
Retired
Unable to work/disabled
Other
Unknown
Missing

89 (3.5)
7 (0.3)
1282 (51.1)
110 (4.4)
73 (2.9)
107 (4.3)
2 (0.1)

Health Insuranceb
Medicare

1350 (53.8)

Preferred provider organization

629 (25.1)

Health maintenance organization

289 (11.5)

Medicaid

109 (4.3)

TRICARE

73 (2.9)

Self-insured

32 (1.3)

Veterans Affairs/Department of
Defense

24 (1.0)

Otherc

353 (14.1)

None

16 (0.6)

Patient Residency Setting
At home, living independently

2381 (94.9)

At home, living as dependent

93 (3.7)

Assisted living

20 (0.8)

Long-term care facility

3 (0.1)

Other

9 (0.4)

Missing

4 (0.2)

a

First choice as listed in sequence of electronic data captured.
Patients may have been included in more than one health insurance category.
Includes range of health insurance and prescription plans and may include some that are
reported within other categories.

b
c
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Supplemental Table 2 Most Common Comorbid Conditions in
2510 Patients
Condition

N (%)

Select Cardiovascular DiseaseeRelated Conditions
Hypertension

1772 (70.6)

Hyperlipidemia

763 (30.4)

Obesitya

440 (17.5)

Diabetes mellitus

395 (15.7)

History of Cancer in ‡ 1% of Patients

a

Skin

88 (3.5)

Nonmelanoma skin cancer

83 (3.3)

Prostate

73 (2.9)

Breast

48 (1.9)

Malignant melanoma

27 (1.1)

Colon

25 (1.0)

Per discretion of managing physician.
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